Tarsus Pharmaceuticals, Inc. $TARS Position Increased by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 26.3% in the first quarter, Holdings Channel.com reports. The institutional investor owned 42,087 shares of the company’s stock after buying an additional 8,764 shares during the period. E. Ohman J or Asset Management AB’s holdings in Tarsus Pharmaceuticals were worth $2,952,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Comerica Bank increased its position in shares of Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after acquiring an additional 705 shares in the last quarter. Truvestments Capital LLC raised its holdings in shares of Tarsus Pharmaceuticals by 106.1% during the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after acquiring an additional 468 shares during the period. Rockefeller Capital Management L.P. lifted its position in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after acquiring an additional 172 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after acquiring an additional 2,462 shares in the last quarter. Finally, Leonteq Securities AG acquired a new position in Tarsus Pharmaceuticals in the 4th quarter worth approximately $164,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, Director Katherine Goodrich sold 2,954 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.08, for a total value of $183,384.32. Following the transaction, the director owned 2,233 shares in the company, valued at $138,624.64. The trade was a 56.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the completion of the transaction, the director directly owned 106,786 shares in the company, valued at approximately $6,633,546.32. The trade was a 10.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 29,850 shares of company stock worth $1,837,321 over the last 90 days. 9.64% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on TARS. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Monday, May 4th. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Guggenheim lifted their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $90.67.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS opened at $63.16 on Monday. The firm has a fifty day moving average of $63.18 and a two-hundred day moving average of $69.31. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12-month low of $38.51 and a 12-month high of $85.25. The firm has a market capitalization of $2.72 billion, a P/E ratio of -55.40 and a beta of 0.49.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. The business had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. On average, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.